Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fate Therapeutics (NQ: FATE )

24.96 -1.29 (-4.90%)
Streaming Delayed Price Updated: 2:53 PM EDT, Jun 28, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 758,852
Open 26.26
Bid (Size) 24.95 (2)
Ask (Size) 24.97 (1)
Prev. Close 26.25
Today's Range 24.55 - 26.81
52wk Range 17.10 - 97.06
Shares Outstanding 96,629,085
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Will Another Enlivex Innovation Break The Glass Ceiling For Solid Tumor Treatments?
Cell therapy — the use of stem cells and various engineered immune cells to target difficult-to-treat diseases like cancer and autoimmune conditions — has arguably been one of the big breakthroughs in... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022
 
Via Benzinga

Performance

YTD
-58.58%
-58.58%
1 Month
+8.07%
+8.07%
3 Month
-34.30%
-34.30%
6 Month
-56.85%
-56.85%
1 Year
-71.99%
-71.99%

More News

Read More
Recap: Fate Therapeutics Q1 Earnings
Via Benzinga
Earnings Scheduled For February 28, 2022
Via Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Via Benzinga
What 4 Analyst Ratings Have To Say About Fate Therapeutics
Via Benzinga
Fate Therapeutics: Q4 Earnings Insights
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Via Benzinga
Fate Therapeutics's Earnings: A Preview
Via Benzinga
Earnings Outlook For Fate Therapeutics
Via Benzinga
2 Natural-Killer Cell Therapy Oncology Companies Investors Should Watch
Via Benzinga
Benzinga Asks: Which ARK Fund Would You Rather Buy And Hold For 5 Years?
Via Benzinga
Here's How Much $100 Invested In Fate Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Via Benzinga
The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks
Via Benzinga
Fate Therapeutics Showcases Interim Data From FT596 Cell Program In Lymphoma
Via Benzinga
Hedge Funds Are Selling Vontier Corporation
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021
Via Benzinga
Cathie Wood Likes Fate Therapeutics, Should You?
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2021
Via Benzinga
Fate Therapeutics, inc (FATE) Q3 2021 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
3 Biotech Stocks to Watch Now
Via Benzinga
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Via Benzinga
Exposures COVID-19
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.